...A. Highlights: Continued to execute well across various facets of business, driving strong revenue growth, achieving success in regulatory actions and key clinical programs, while further improving sound financial position. 1. 2. Jakafi grew 16% YoverY to reach $474m. 3. Jakavi and Olumiant royalties grew 16% and 35%, respectively. 4. Reports six sources of product and royalty revenues for the first time, with approvals of Pemazyre and Tabrecta. Total product and royalty revenues, $593m. a. i. Up 16% YoverY. 5. Announced two product approvals since Co. reported 1Q, including: Tabrecta, licensed to Novartis. a. b. Just recently, received first approval for Monjuvi in collaboration with MorphoSys. i. First FDA approved therapy for second-line treatment of adults with DLBCL. ii. Believes it has potential to transform treatment of patients with relapsed or refractory disease. 6. Announced the positive results of REACH3, the largest randomized clinical trial ever conducted in steroid-refractory...
